DNA Patterns as Early Indicators for Blood Cancer Progression

New research indicates that DNA patterns may reveal the progression of certain blood cancers years before conventional tests detect changes. The study, published in Cancer Discovery by the American Association for Cancer Research, focused on 30 individuals with myeloproliferative neoplasms (MPNs). In these blood cancers, the bone marrow produces an excess of blood cells.

Researchers tracked DNA in patients’ blood and bone marrow to identify genetic changes. They studied whether these changes were linked with blood counts, stable conditions, or progression to more severe diseases like myelofibrosis or acute leukemia.

People with stable conditions often exhibited stable DNA, without cancer-linked genetic changes, suggesting a genetically ‘quiet’ MPN might remain stable. This observation comes from researchers based at the Wellcome Trust Sanger Institute in the UK.

Patients whose diseases worsened frequently showed DNA changes years before routine tests spotted progression. This occurred as new abnormal cell groups emerged and grew. Nine participants progressed to acute myeloid leukemia (AML), but not uniformly.

Some saw MPN cells accumulating harmful mutations, while others saw leukemia arising from different abnormal cell groups. Similar patterns were seen in those developing myelofibrosis.

The study also noted that hydroxyurea, a medication used to manage blood counts in MPN patients, imprinted a distinct pattern of small DNA changes. No link was found between the drug and leukemia. Azacitidine, used for certain blood cancers, exhibited a similar DNA impact.

Genetic changes sometimes surfaced years before routine tests identified disease progression. Three participants with ‘triple-negative’ essential thrombocythemia, a condition considered a blood cancer, showed no genetic cancer signs in their samples. This finding suggests some diagnosed patients might not have a malignant disease and might avoid long-term cancer treatment.

The study’s small sample size limits its influence, demonstrating associations without establishing cause and effect.

Abhishek Chilkulwar, M.D., an oncologist not involved in the study, emphasized that many with MPNs can live decades with them. He acknowledged that the DNA of these blood cancers might reveal their future courses long before symptoms arise, marking a step toward precision medicine.

DNA changes can indicate the development of specific cancers a decade prior to diagnosis, with a patient’s genetic path potentially predating any visible signs.

Chilkulwar suggested that monitoring a patient’s DNA regularly might alert doctors to impending disease progression, far ahead of routine blood tests.

Looking forward, pairing early genetic detection with mutation-specific drugs could potentially prevent or delay disease progression. The aim is for closer monitoring rather than new treatment approaches in the short term. Patients with acquired high-risk mutations could need more frequent blood counts and possibly bone marrow checks.

The idea is not to preemptively initiate procedures such as stem cell transplants, which are reserved for progressed cases like myelofibrosis or AML.

Advancements could lead to genetic detection combining with targeted drugs to prevent or delay disease advancement.